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ABSTRACT 
Background:  Hepatitis C is an infectious disease of the liver caused by the hepatitis C virus (HCV) resulting to a chronic 
hepatitis. Chronic HCV infection constitutes a serious public health challenge in Nigeria where donor blood is not 
routinely screened for HCV. Patients with sickle cell anaemia (SCA) are considered a subset of the population at higher 
risk of acquiring the virus, due to their frequent needs for transfusion of blood and its products. Other risk factors like 
scarification markings, tattooing, and circumcision also predispose children to acquiring this infection. However, the 
magnitude of HCV infection has not been adequately measured in our general population and specific data on HCV in 
SCA patients are scanty, hence a prospective case controlled study to determine the risk factors that predispose to the 
acquisition of hepatitis C Virus infection. 
Objective: To determine the risk factors for Hepatitis C Virus Antibody Seropositivity among transfused children with 
SCA in Ilorin. 
Subjects and Method: Eighty two transfused SCA children aged 6 months to 14 years were recruited consecutively from 
February 2008 to January 2009 while eighty four non transfused SCA children of the same age range recruited over the same 
period served as controls. Hepatitis C virus Antibody screening was done using a second generation ELISA method. 
Information on the study population were collected by use of a pretested questionnaire by the investigator.  
Results: There was a positive correlation between numbers of units of blood transfused and seropositivity. Those who had 
three or more units of blood had a prevalence rate of more than 50%. There was a strong correlation between seropositivity 
and scarification marks in both subjects and controls (p=0.001 and 0.02 respectively). Other plausible risk factors for 
hepatitis C infection tested in this study included circumcision and sharing of clippers which showed no statistically 
significant difference. No cases of tattooing, drug abuse, needle sharing or sexual activities were seen in this study. 
Conclusion: Transfused SCA patients belong to a high risk group for hepatitis C virus infection compared to the non-
transfused population. The risk of acquisition increases with higher number of transfusions and scarifications marks. 
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INTRODUCTION 
 The Hepatitis C virus (HCV)  has become an 
important cause of chronic liver disease and liver 
cancer worldwide(2).  Hepatitis C Virus  infection is 
highly prevalent in Africa, however  the 
epidemiology of this infection is yet to be well 
defined (1).  Hepatitis C virus infection  has been 
found to lead to chronicity in 70-85% of cases(3), 
which is similar to hepatitis B virus infection (HBV) 
which becomes chronic in about 75% of individuals 
infected (4). It is estimated that about 170million 
people worldwide are chronically infected with 
HCV and majority are in developing countries.5 
About 30% of those infected with HCV will 
progress to liver cirrhosis and ultimately to end 
stage liver failure and hepatic carcinoma (3,4,6). It is 
one of the agents transmissible by blood transfusion 
and is now known to be the major cause of non-A, 
non-B post transfusion hepatitis (NANBH) (7). The 
risk factors that are associated with transmission of 
both HCV and HBV infections are transfusion of 
blood and blood products, tattooing, scarification 
with re-usable instruments, body piercing, 
injection/illicit drug use, perinatal transmission and 
multiple sex partners (5,8).  Since HCV was first 
identified (9,10), one of the best known and most 
extensively studied routes of its transmission has 
been blood and blood derivative transfusion (11,12), 
therefore patients at risk for HCV infection include 
transfusion dependent   Haemophiliacs, 
homozygous β-Thalassaemia and Sickle cell 
anaemia (SCA)  patients (13). 
The commonest condition in Nigeria for which 
patients receive repeated blood transfusion is SCA 
(14)., which has a prevalence of 1.6-3% in Nigeria 
(15). 
In Japan, unsafe injections as in the use and re-use 
of unsterilized needles in the practice of 
acupuncture and related techniques have been 
documented as significant routes of HCV 
transmission (2).  Kaine  et al (16) estimated that 2.3 
to 4.7 million HCV infections annually might be 
caused by similar unsafe injections in developing 
countries. 
In Nigeria, patients with Sickle Cell Anaemia (SCA) 
represent the group most likely to receive multiple 
blood transfusions. Severe anaemia crisis often 
complicated by malaria parasitaemia and other 
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infections constitute the major indications for blood 
transfusion (2). The risk of transfusion acquired 
HCV infection and its potentially devastating 
consequences are clearly greater in this 
environment where re-donor HCV screening is not 
standard practice (2). 
In the present study, we hope to estimate the role of 
blood transfusion and other risk factors in the 
transmission of HCV infection. 
 
SUBJECTS AND METHODS 
The study was carried out at the University of Ilorin 
Teaching Hospital (UITH) Ilorin, Nigeria. The 
hospital has a well established sickle cell clinic that 
serves the north-central and south-west Nigeria. 
The University of Ilorin Teaching Hospital 
(U.I.T.H.) is a tertiary health facility that serves as a 
referral centre for Kwara, Kogi, Niger, Osun and 
Ekiti States of Nigeria and also offers secondary 
health services to the public. It runs a well-
established Sickle Cell Disease Clinic for patients 
below the age of 14 years. An average of 30 mainly 
old and few new patients are seen in the clinic 
every Monday. On attaining the age of 14 years 
such individuals are transferred to the adult Sickle 
Cell Disease Clinic of the same hospital. The 
hospital provides a blood transfusion service and 
laboratory that screens blood for antibodies to 
HCV. 
 
Eighty-two transfused SCA children aged 6 months 
to 168 months were recruited consecutively from 
February 2008 to January 2009 while 84 non 
transfused SCA children of the same age range 
recruited over the same period served as controls. 
Antibodies to HCV screening were done using a 
second generation ELISA method. The age of the 
subjects in this study were taken as their completed 
months at recruitment. The subjects were 
transfused at least 6 months before presentation to 
be eligible for the study. 
 
Haemoglobin (Hb) electrophoresis was carried out 
using electrophoretic tank (Volkman SAE 2761) 
with cellulose acetate paper at pH 8.4 to confirm 
their status in the Haematology department of 
U.I.T.H Ilorin. A pretested questionnaire was used 
to obtain information on age, sex, history of blood 
transfusion, parents’ educational level as well as 
occupation to obtain their social class. 
 
Ethical clearance was obtained from the Ethical 
Review Committee of the hospital and official 
permission obtained from the head of the 
Haematology Department. After a clear explanation 
of the project to them, informed consent was also 
obtained from either or both parents/guardian and 
the children before subject enrolment. 
 
Five milliliters of venous blood was collected 
fromeach subject after a verbal consent and then 
transported to the laboratory where the serum was 
separated and assayed for antibodies to HCV 
immediately using a 2nd generation HCV one step 
hepatitis C virus test strip manufactured by 
Acumen diagnostic incorporated, USA112 which is a 
Rapid Chromatographic Immunoassay for the 
qualitative detection of antibody to HCV in serum 
was used for HCV analysis. The sensitivity and 
specificity of the test strip were 99.6% and 99.5% 
respectively. 
Statistical analysis was done using SPSS statistical 
package. The chi-square test was used to assess the 
significance of the difference amongst the groups 
and a p-value of <0.05 was considered significant. 
 
RESULTS 
A total of 82 transfused sickle cell anaemia patients 
and 84 non-transfused sickle cell anaemia patients 
were recruited into the study. The male to female 
ratio was 1.6:1 in the subjects and 1.1:1 in the 
controls. The mean age of the subjects and the 
controls were 95.8+ 48.7 months and 93.5 + 54.0 
months respectively and are comparable (p = 0.77). 
Table I. Table II shows that five of the children had 
detectable antibodies to HCV, constituting 3% of 
the total population studied, giving an overall 
hospital-based prevalence of Hepatitis C infection 
in sickle cell anaemia (SCA) to be 3%. The 
prevalence of anti-HCV in both the subjects and the 
controls were comparable (p = 0.68), as shown in 
Table II below. 
 
Table III shows that the subjects and controls were 
comparable in terms of social stratification in 
classes I, IV and V, but more controls were in social 
classes II and more subjects in social class III in the 
subjects (p = 0.003 and 0.002 for classes II and III 
respectively). There is no significant difference in 
the seroprevalence of HCV infection in the low and 
high social classes, (Table IV) both in the subjects 
and controls. 
 
Table V shows that among the subjects, anti-HCV 
seropositivity increased with the number of units of 
blood transfused. This increase was such that 2.2% 
of recipients of 1-2 units and 6.9% of recipients of 3-
4 units were anti-HCV positive. 
All the subjects received blood transfusion at one 
time or the other with the number of transfusions 
ranging from 1 to 13 units with a mean of 2.63 +  
1.67 units per subject. A patient in the age group 
121 to 168 months received greater than eight units 
of blood 
 
Table VI shows other risk factors studied and 
shows that; 
Circumcision: Two (66.7%) of the anti-HCV positive 
subjects were not circumcised while 1(33.3%) was 
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circumcised but the difference is not significant (p = 
0.3). 
Sharing of clippers: Sixty six percent of the anti-
HCV positive subjects shared clippers, while 
1(33.3%) never shared clippers. All the controls that 
are anti-HCV positive shared clippers. There was 
no significant difference whether the patient shared 
clippers or not in both controls and subjects (p = 
0.12 for subjects and 0.41 for controls). 
Scarification marks: All the three subjects and the 
two control patients that are positive for anti-HCV 
had scarification marks (p = 0.001 for subjects and 
0.02 for controls). Other risk factors looked into 
were not found in the patients recruited into the 
study as depicted in table VI.  
 






      Total 
        
      n (%) 
      Subjects 
       
       n (%) 
       Controls 
       
        n (%) 
Male        93(56)       50(61)        43(51.2) 
Female        73(44)       32(39)        41(48.8) 
Total      166(100)       82(100)        84(100) 
  
Age group in months 
   
6 – 60      60(36.2)       29(35.4)        31(36.9) 
61 – 120      52(31.3)       27(32.9)        25(29.8) 
121 – 168 
 
Mean age 
     54(32.5)       26(31.7) 
      
 95.8+ 48.7 
       28(33.3) 
       
 93.5+ 54.0** 
 
   **p=0.77 
 
TABLE II: THE ANTI- HCV SEROPOSITIVITY IN THE SUBJECTS AND CONTROLS. 
 Anti-HCV positive     Anti-HCV negative  Total 
 
 n(%)                           n(%)                          n(%)           χ2     p 
Subjects                3(3.7)                          79(96.3)                     82(100)       
Controls               2(2.4)                          82(97.6)                     84(100)      0.23  0.68 
                                    
























      I    11 5(45.5) 6(54.5) 0.18 0.67 
     II    60 22(36.7) 38(63.3) 8.53 0.003 
    III    70 44(62.9) 26(37.1) 9.26 0.002 
    IV    22 10(45.5) 12(54.5) 0.36 0.54 
    V    3 1(66.7) 2(33.3) 0.00 1.00 
 
TABLE IV:   ANTI-HCV POSITIVITY IN SUBJECTS AND CONTROLS ACCORDING TO SOCIAL CLASS 
 
 Subjects   Controls   
Social class Anti-HCV 
positive 


















I 0 5(100) 5 0 6(100) 6 
II 1(4.5) 21(95.5) 22 1(2.6) 37(97.4) 38 
III 1(2.3) 43(97.7) 44 1(3.8) 25(96.2) 26 
IV 0 10(100) 10 0 12(100) 12 
V 1(100)  0 1 0 2(100) 2 
Categorised social 
class  
      
Low(III-V) 2(3.6) 53(96.4) 55 1(2.5) 39(97.5) 40 
High(I-II) 1(3.7) 26(96.3) 27 1(2.3) 43(97.7) 44 













































1-2 1(2.2) 45(97.8) 46    
3-4 2(6.9) 27(93.1) 29 0.30 0.01-4.54 0.33 
5-8 0 61(100) 61 - - - 
>8 0 1(100) 1    
*=Odds ratio.                **=95% Confidence interval. 
 
TABLE VI: THE RISK FACTORS FOR ANTI- HCV POSITIVITY IN THE SUBJECTS AND CONTROLS. 
 
























 n (%) 
 
Negative 










Circumcision           
Circumcised  1(2.2) 45(97.8) 46(100)   2(4.2) 46(95.8) 48(100)   

















       
0.27 
        
 
0.3 
Sharing of clippers           
Shared clipper 2(5.6) 34(94.4) 36(100)   2(6.7) 28(93.3) 30(100)   



















   
0.12                 
Scarification marks           
Scarification 3(30) 7(70) 10(100)   2(16.7) 10(83.3) 12(100)   
No scarification 0 72(100) 72(100) 14.72 
 
0.001 0 72(100) 72(100) 6.17 
 
0.02 
Blood transfusion           




Abuse of drug 







































   
FIGURE 1: BAR CHART SHOWING THE UNITS OF BLOOD TRANSFUSED IN THE DIFFERENT AGE GROUPS 
AMONGST THE SUBJECTS. 
 
DISCUSSION 
In this study, the seroprevalence rate of anti
3.7% in the transfused sickle cell anaemia (SCA) 
patients and 2.4% in the controls that were not 
transfused, a finding that is similar to previous 
reports.2,4  
An overall prevalence of 3% was detected in sickle 
cell anaemia patients generally, with a higher 
prevalence of 3.7% in transfused patients, and 2.4% 
in non-transfused sickle cell anaemia patients.  
These values parallels the frequency of HCV 
infection in the world population in general 
estimated at 3%4, while the frequency among SCA 
patients submitted to transfusion of blood or blood 
derivatives reported in the literature ranges from 2
30%. 2,5-9,15  In the present study, the ages of children 
screened for hepatitis C virus antibody falls 
between 6 months and one hundred and sixty
months with children within the age range six to 
sixty months having the highest percentage of 
seropositivity of 36.2% whilst children between the 
age of sixty one to a hundred and twenty having 
the lowest percentage of 31.3%. Sickle cell anaemia 
patients who received multiple blood transfusions 
did not appear to be at a greater risk of acquiring 
hepatitis C virus infection since the prevalence is 
comparable in the transfused cases and non 
transfused controls suggesting that blood 
transfusion may not be the only or major route 
transmission. 
 
The patients were evenly distributed in the five 
social classes and the subjects and controls were 
comparable except in social classes two and three 
where the differences in the subjects and controls 
were statistically significant. Over two
















socioeconomic class, a finding that is similar to 
other reports from the Niger delta17
and in the USA.18  This can be attributed to the 
poverty and resultant ignorance and poor h
seeking behaviour of this group of people.
There was also no correlation in prevalence 
between multi-transfused and non-transfused sickle 
cell anaemia patients, a finding that is similar to 
earlier reports2,14 but at variance with others,
reported a higher prevalence with multi
SCA patients. Since multi-transfused SCA patients 
did not appear to be at a greater risk, blood 
transfusion may not be the only or major route of 
transmission. There was a linear correlation 
between the prevalence of anti-HCV and increasing 
number of units of blood transfused and this is 
similar to the trend in other studies.
highest prevalence was in those who had more than 
3 units of blood.  This is comparatively higher than 
those that received more than 10 units of blood in 
both US studies with seroprevalence of 23% and 
30%.16,20  
 
The higher magnitude of the risk of positivity with 
each transfusion in the Nigerian studies may 
suggest that more contaminated blood is being 
transfused. This is not surprising considering that 
blood is not usually screened for HCV antibodies, it 
is therefore pertinent that blood be given only when 
necessary and blood for transfusion should also be 
screened for Hepatitis C virus antibodies.
Tribal marks, male and female circumcision, 
medicinal and other scarifications, all of which are 
common practices in this environment correlates 
well with a high seropositivity. Of the other risk 
factors considered none of the patients had tattoo 














1-2 units 3-4 units
5-8 units > 8 units










or shared needles. Some of the patients that were 
positive for anti-HCV were circumcised, shared 
clippers but these were not statistically significant. 
 
 It is interesting to note that all the 3 subjects and 2 
control patients that were positive for anti-HCV 
had scarification marks for various reasons ranging 
from family culture to therapeutic indications. Most 
of the scarifications and sociocultural practices were 
done by Herbalists using crude methods involving 
sharp reusable and scientifically unsterilized 
devices.  
 
It is plausible to suggest that engagement in these 
activities as verified in the cases that were positive 
for HCV antibodies could have exposed these 
patients to infection with Hepatitis C virus. This 
finding is in consonance with an earlier work in 
adults and blood donors carried out in Ilorin.22 
There is therefore the need for a larger survey in 
children to ascertain if this is a possible major route 
of transmission. Despite the high prevalence of 
other potential risk factors, only previous 
scarification marks and previous history of blood 
transfusion was associated with HCV antibody 
positivity in this study. Whatever the source of 
infection, screening of blood and blood products 
alone may not prevent the transmission of HCV 
infection effectively in this environment. Increasing 
awareness of the disease and its route of 
transmission, adequate enlightenment of the 
general population as well as health care workers 
on safe medical practices could make a significant 
impact on the spread of HCV infection. 
Furthermore, premarital antenatal counseling and 
screening for sickle cell disease will contribute to a 
decrease in prevalence through a corresponding 
decrease in the sickle cell gene frequency. 
 
Transmission of HCV infection resulting from 
unsafe injections is being increasingly described 
and recent epidemiology in developing countries 
suggests that this and other sporadic non 
transfusion related routes which had previously 
been grossly underestimated, maybe the important 
routes of HCV transmission2 In Japan, tattooing, 
scarification marks and the use of unsterilized 
needles in the practice of folk medicine including 
acupuncture and related techniques has been 
documented as significant routes of transmission. 
All these are in agreement with the findings of this 
study. 
Larger studies are necessary to address the role of 
other risk factors like scarification marking, unsafe 
injections, use of public clippers as well as blood 
transfusion  in the transmission of HCV infection.  
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